Graybill Bartz & Assoc Ltd. boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,001 shares of the medical research company’s stock after acquiring an additional 69 shares during the quarter. Thermo Fisher Scientific accounts for approximately 3.2% of Graybill Bartz & Assoc Ltd.’s holdings, making the stock its 6th largest position. Graybill Bartz & Assoc Ltd.’s holdings in Thermo Fisher Scientific were worth $4,699,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in TMO. Truvestments Capital LLC purchased a new stake in Thermo Fisher Scientific during the 1st quarter valued at $29,000. CX Institutional purchased a new stake in Thermo Fisher Scientific during the 1st quarter valued at $36,000. Focused Wealth Management Inc purchased a new stake in Thermo Fisher Scientific during the 2nd quarter valued at $44,000. Somerset Trust Co raised its stake in Thermo Fisher Scientific by 162.7% during the 1st quarter. Somerset Trust Co now owns 197 shares of the medical research company’s stock valued at $54,000 after buying an additional 122 shares during the last quarter. Finally, Farmers & Merchants Trust Co of Chambersburg PA raised its stake in Thermo Fisher Scientific by 168.0% during the 1st quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 201 shares of the medical research company’s stock valued at $55,000 after buying an additional 126 shares during the last quarter. 88.02% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE:TMO traded down $5.27 during midday trading on Monday, hitting $269.55. The company had a trading volume of 8,667 shares, compared to its average volume of 1,393,107. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.07 and a current ratio of 1.49. The firm has a market cap of $109.92 billion, a P/E ratio of 24.21, a price-to-earnings-growth ratio of 1.80 and a beta of 1.11. Thermo Fisher Scientific Inc. has a 12-month low of $208.34 and a 12-month high of $305.45. The business has a fifty day simple moving average of $291.36.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $3.04 EPS for the quarter, topping the consensus estimate of $3.01 by $0.03. The firm had revenue of $6.32 billion during the quarter, compared to analyst estimates of $6.31 billion. Thermo Fisher Scientific had a return on equity of 17.11% and a net margin of 14.24%. Thermo Fisher Scientific’s revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the business posted $2.75 EPS. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 12.23 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Tuesday, September 17th will be paid a $0.19 dividend. The ex-dividend date is Monday, September 16th. This represents a $0.76 annualized dividend and a dividend yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 6.83%.
TMO has been the subject of a number of research reports. UBS Group boosted their target price on shares of Thermo Fisher Scientific from $305.00 to $320.00 and gave the company a “buy” rating in a research note on Thursday, May 23rd. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $299.00 target price for the company in a research note on Wednesday, June 12th. Needham & Company LLC boosted their target price on shares of Thermo Fisher Scientific from $315.00 to $321.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Credit Suisse Group reiterated a “buy” rating and set a $310.00 target price on shares of Thermo Fisher Scientific in a research note on Wednesday, July 31st. Finally, BTIG Research boosted their target price on shares of Thermo Fisher Scientific to $320.00 and gave the company a “buy” rating in a research note on Thursday, May 23rd. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $303.17.
In other news, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction on Tuesday, July 30th. The stock was sold at an average price of $284.83, for a total value of $14,241,500.00. Following the completion of the sale, the chief executive officer now directly owns 342,193 shares in the company, valued at approximately $97,466,832.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Stephen Williamson sold 2,500 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $268.29, for a total value of $670,725.00. Following the completion of the sale, the chief financial officer now owns 40,029 shares of the company’s stock, valued at $10,739,380.41. The disclosure for this sale can be found here. Insiders sold a total of 52,775 shares of company stock valued at $14,986,676 over the last 90 days. 0.45% of the stock is currently owned by company insiders.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Featured Article: Why investors pay attention to retained earnings
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.